KSK

Vital KSK Holdings is a leading Japanese pharmaceutical wholesaler and healthcare services group formed through the merger of Vital-Net and KSK. While its core business remains the distribution of pharmaceuticals, medical devices, and reagents across Japan, the company has recently expanded into drug development through its subsidiary, MedLeap Pharma. This strategic shift focuses on addressing unmet medical needs and reducing 'drug lag' in the Japanese market. The company's lead development program involves repurposing ferric maltol for the treatment of pulmonary arterial hypertension (PAH), currently in Phase 2 clinical trials in Japan.